STVN vs APOG vs BCPC vs BDX vs WST

For growth investors, Balchem Corporation (BCPC) is the stronger pick with 8.

8% revenue growth year-over-year, versus 3. 2% for Stevanato Group S. p. A. (STVN). Apogee Enterprises, Inc. (APOG) offers the better valuation at 14. 5x trailing P/E (10. 6x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Apogee Enterprises, Inc.

(APOG) is the cheapest at 14. 5x versus West Pharmaceutical Services, Inc. at 47. 3x. On forward P/E, Apogee Enterprises, Inc. is actually cheaper at 10. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Apogee Enterprises, Inc. wins at 0. 32x versus West Pharmaceutical Services, Inc. 's 4. 51x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Balchem Corporation (BCPC) delivered a total return of +24.

2%, compared to -7. 2% for Stevanato Group S. p. A. (STVN). Over 10 years, the gap is even starker: WST returned +361. 4% versus STVN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Balchem Corporation (BCPC) is the lower-risk stock at 0.

33β versus Stevanato Group S. p. A. 's 1. 45β — meaning STVN is approximately 340% more volatile than BCPC relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Balchem Corporation (BCPC) is pulling ahead at 8.

8% versus 3. 2% for Stevanato Group S. p. A. (STVN). On earnings-per-share growth, the picture is similar: Balchem Corporation grew EPS 20. 9% year-over-year, compared to -35. 2% for Apogee Enterprises, Inc.. Over a 3-year CAGR, STVN leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus 3. 9% for Apogee Enterprises, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCPC leads at 21. 1% versus 6. 0% for APOG. At the gross margin level — before operating expenses — BDX leads at 45. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Apogee Enterprises, Inc. (APOG) is the more undervalued stock at a PEG of 0. 32x versus West Pharmaceutical Services, Inc. 's 4. 51x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Apogee Enterprises, Inc. (APOG) trades at 10. 6x forward P/E versus 37. 3x for West Pharmaceutical Services, Inc. — 26. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for APOG: 92. 7% to $70. 50.

All stocks in this comparison pay dividends.

Apogee Enterprises, Inc. (APOG) offers the highest yield at 2. 8%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).

For long-horizon retirement investors, Balchem Corporation (BCPC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), 0. 5% yield, +160. 5% 10Y return). Both have compounded well over 10 years (BCPC: +160. 5%, STVN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (STVN (Healthcare) and APOG (Industrials) and BCPC (Basic Materials) and BDX (Healthcare) and WST (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: STVN is a small-cap quality compounder stock; APOG is a small-cap deep-value stock; BCPC is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock; WST is a mid-cap quality compounder stock. APOG, BCPC, BDX pay a dividend while STVN, WST do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.